Molecular gene expression and genome wide profiling in tamoxifen-resistant breast cancer
Oestrogen receptor positive (ER+) breast cancers (BC) are heterogeneous in both their clinical behaviour and response to therapy. The ER and Progesterone (PgR) are currently the best predictors of response to the anti-oestrogen tamoxifen, yet up to 40% of ER+ breast cancer will relapse despite tamox...
| Main Author: | |
|---|---|
| Published: |
Queen Mary, University of London
2010
|
| Subjects: | |
| Online Access: | https://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.528401 |